124 related articles for article (PubMed ID: 35858533)
1. Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study.
Arnold D; Eggers E; Uhlig J; Reichert D; Becker L; Thiebach L
Oncol Res Treat; 2022; 45(10):576-587. PubMed ID: 35858533
[TBL] [Abstract][Full Text] [Related]
2. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
3. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Nakayama G; Uehara K; Ishigure K; Yokoyama H; Ishiyama A; Eguchi T; Tsuboi K; Ohashi N; Fujii T; Sugimoto H; Koike M; Fujiwara M; Ando Y; Kodera Y
Cancer Chemother Pharmacol; 2012 Oct; 70(4):575-81. PubMed ID: 22886005
[TBL] [Abstract][Full Text] [Related]
5. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice.
Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
[No Abstract] [Full Text] [Related]
7. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
8. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
Masi G; Salvatore L; Boni L; Loupakis F; Cremolini C; Fornaro L; Schirripa M; Cupini S; Barbara C; Safina V; Granetto C; Fea E; Antonuzzo L; Boni C; Allegrini G; Chiara S; Amoroso D; Bonetti A; Falcone A;
Ann Oncol; 2015 Apr; 26(4):724-730. PubMed ID: 25600568
[TBL] [Abstract][Full Text] [Related]
9. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF
Tabernero J; Grothey A; Arnold D; de Gramont A; Ducreux M; O'Dwyer P; Tahiri A; Gilberg F; Irahara N; Schmoll HJ; Van Cutsem E
ESMO Open; 2022 Oct; 7(5):100559. PubMed ID: 36029653
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
[TBL] [Abstract][Full Text] [Related]
11. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
Khakoo S; Chau I; Pedley I; Ellis R; Steward W; Harrison M; Baijal S; Tahir S; Ross P; Raouf S; Ograbek A; Cunningham D;
Clin Colorectal Cancer; 2019 Dec; 18(4):280-291.e5. PubMed ID: 31451367
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
[TBL] [Abstract][Full Text] [Related]
13. A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon.
Temraz S; Nasr F; Kattan J; Abigerges D; Moukadem W; Farhat F; Maatouk L; Chahine G; Shamseddine A
Biologics; 2022; 16():7-15. PubMed ID: 35221671
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
15. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Yamamoto S; Nagashima K; Kawakami T; Mitani S; Komoda M; Tsuji Y; Izawa N; Kawakami K; Yamamoto Y; Makiyama A; Yamazaki K; Masuishi T; Esaki T; Nakajima TE; Okuda H; Moriwaki T; Boku N
BMC Cancer; 2021 Oct; 21(1):1159. PubMed ID: 34715820
[TBL] [Abstract][Full Text] [Related]
18. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
Suzuki T; Shinozaki E; Osumi H; Nakayama I; Ota Y; Ichimura T; Ogura M; Wakatsuki T; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
Cancer Chemother Pharmacol; 2019 Aug; 84(2):307-313. PubMed ID: 31065729
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Stein A; Petersen V; Schulze M; Seraphin J; Hoeffkes HG; Valdix AR; Schroeder J; Herrenberger J; Boxberger F; Leutgeb B; Hinke A; Kutscheidt A; Arnold D
Acta Oncol; 2015 Feb; 54(2):171-8. PubMed ID: 25307517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]